Background: Glycated haemoglobin A1c (HbA1c) has limitations as a glycemic marker for
patients with diabetes and CKD and for those receiving dialysis. Glycated albumin is an …

Diabetes mellitus (DM) and chronic kidney disease (CKD) are intricately intertwined. DM is
the most common cause of CKD. Adequate control of DM is necessary for prevention of …

Diabetic kidney disease is highly prevalent in patients with type 2 diabetes and is a major
cause of end-stage renal disease in Switzerland. Patients with diabetic kidney disease are …

Introduction: Shortened erythrocyte life span and erythropoietin-stimulating agents may
affect hemoglobin A 1c (HbA 1c) levels in patients receiving peritoneal dialysis (PD). We …

People treated with peritoneal dialysis (PD) often have complicating conditions that require
careful management. Three such conditions are reviewed in this article–diabetes mellitus …

Background and aim: Over the past decades, glycosylated haemoglobin (HbA1c) has been
a gold standard for monitoring diabetes control over a long period, relative to blood glucose …

Objectives: Peritoneal dialysis requires mental and physical adjustments. The purpose of
this chapter is to describe some of the psychosocial adaptations that patients and their …

Kontinuerlig glukosemonitorering (CGM) blev godkendt i 1999 af US Food and Drug
Administration og vinder stigende udbredelse i glukosemonitorering ved diabetes. Endnu er …

Compared with hospital based therapies, peritoneal dialysis (PD) offers many advantages to
patients with end stage renal disease in terms of greater autonomy and independence in …